We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Veru Inc (VERU) USD0.01

Sell:$1.38 Buy:$1.39 Change: $0.03 (2.11%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
Sell:$1.38
Buy:$1.39
Change: $0.03 (2.11%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
Sell:$1.38
Buy:$1.39
Change: $0.03 (2.11%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Contact details

Address:
2916 N. MIAMI AVENUE, SUITE 1000
MIAMI
33127
United States
Telephone:
+1 (312) 5959123
Website:
https://verupharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VERU
ISIN:
US92536C1036
Market cap:
$207.87 million
Shares in issue:
146.38 million
Sector:
Personal Care Products
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Mitchell Steiner
    Chairman of the Board, President, Chief Executive Officer
  • Harry Fisch
    Vice Chairman of the Board, Chief Corporate Officer
  • Michele Greco
    Chief Financial Officer, Chief Administrative Officer
  • K. Gary Barnette
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.